The Biopharmaceutical company focused on the biology of healing, last week reported FY December 2015 results. Revenues at C$24.5m were just ahead of our expectations. Encouragingly product sales made up the majority of this (a record C$21.4m up 98%) with service revenues diminishing in importance as Prometic seeks to commercialise its own extensive commercial property. Consequently R&D investment has now hit the $50m level and overall net losses of C$56.8m were 8.4% less than our projecti
07 Apr 2016
Financial and clinical strength
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Financial and clinical strength
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
07 Apr 2016 -
Author:
Derren Nathan -
Pages:
7
The Biopharmaceutical company focused on the biology of healing, last week reported FY December 2015 results. Revenues at C$24.5m were just ahead of our expectations. Encouragingly product sales made up the majority of this (a record C$21.4m up 98%) with service revenues diminishing in importance as Prometic seeks to commercialise its own extensive commercial property. Consequently R&D investment has now hit the $50m level and overall net losses of C$56.8m were 8.4% less than our projecti